Clinical Trial Update: A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable [Phase 2]

View source ↗

Summary

Phase 2 study evaluating neoadjuvant bevacizumab (Avastin) in patients with initially unresectable FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer
• Tubal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED